argenx SE
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
Registration date
18 jan 2024 - 07:07
Statutory name
argenx SE
Title
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
Related downloads
Date last update: 02 April 2026